MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

MaxCyte (Nasdaq: MXCT) announced a technology license partnership with Genentech, a member of the Roche Group, to support development of cell therapy programs.

Rhea-AI Summary

MaxCyte (Nasdaq: MXCT) announced a technology license partnership with Genentech, a member of the Roche Group, to support development of cell therapy programs. The agreement provides Genentech access to MaxCyte’s ExPERT GTx platform and additional platform technologies across select research, clinical development, and manufacturing workflows.

The multi-program license is designed to enable ex vivo cell engineering applications and streamline progression from early discovery through cGMP manufacturing. According to MaxCyte, the collaboration brings together complementary capabilities in cell engineering, gene editing, and analytical workflows to support next-generation cell-based therapeutics throughout the development lifecycle.

Positive

• Genentech technology license partnership spanning research, clinical development, and manufacturing workflows
• Multi-program license enabling ex vivo cell engineering applications on MaxCyte platforms

Negative

• None.

News Explained

MaxCyte says it has entered into the technology license partnership with Genentech, rather than merely describing a prospective arrangement; Genentech receives access to MaxCyte platforms for selected research, development, and manufacturing workflows across multiple cell-therapy programs.

Argus Jul 21 session 13 alerts

+5.13% close to close 0.3x rel. volume Open Argus

Details

Market reaction after Multi-platform technology partnership: MXCT +5.13% in the Jul 21 session

-8.9% Trough in 31 hr 31 min

$132.83M Market Cap

In the Jul 21 session, MXCT gained 5.13%, reflecting a notable positive market reaction. Argus tracked a trough of -8.9% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.1% in the session following this news. MaxCyte's May 12 earnings release was foll...

Analysis

The stock moved +5.1% in the session following this news. MaxCyte's May 12 earnings release was followed by a 24.06% 24-hour gain. The partnership adds a corporate-platform validation angle, while the historical record also includes negative reactions to company news.

Key Figures

Announcement date: July 21, 2026 Company history: More than 25 years

Announcement date

July 21, 2026

Technology license partnership announcement

Company history

More than 25 years

Advancing cell engineering

Historical Context

5 past events · Latest: Jul 15

5 events

1. Jul 15

   Earnings date notice

   24h Move

   -4.9%

   Company scheduled second-quarter 2026 results and conference call for August 12

2. May 12

   Quarterly earnings

   24h Move

   +24.1%

   Reported improved net loss, reiterated guidance, and authorized a share repurchase program

3. Apr 29

   Earnings date notice

   24h Move

   +7.6%

   Scheduled first-quarter 2026 results and investor conference call for May 12

4. Mar 31

   Inducement grants

   24h Move

   +5.9%

   Disclosed stock options and restricted stock units tied to the chief financial officer appointment

5. Mar 24

   Annual earnings report

   24h Move

   -6.8%

   Reported declining annual revenue and provided lower 2026 revenue guidance

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

ex vivo, cGMP, gene editing

3 terms

ex vivo medical

"enables Genentech to support ex vivo applications for cell engineering"

Ex vivo describes tests or treatments performed on living cells, tissues, or organs that have been removed from the body and studied in an external environment. For investors, ex vivo work sits between basic lab dish tests and whole‑animal or human studies, offering a more realistic preview of how a therapy or diagnostic might behave in real tissue — like running an engine on a test stand before putting it back into a car — which can reduce scientific risk and inform development milestones.

cGMP technical

"support cell engineering from early discovery to cGMP manufacturing"

cGMP (current Good Manufacturing Practice) are government-enforced quality standards that manufacturers must follow to ensure drugs, medical devices, and related products are made consistently, safely, and meet specified quality tests. For investors, cGMP compliance is like a restaurant passing health inspections: it reduces the risk of product recalls, regulatory fines, or production stoppages that can hurt revenue and company value, and it supports market access and long-term trust.

gene editing technical

"complementary capabilities in cell engineering and gene editing"

Gene editing is a set of laboratory techniques that change the DNA inside living cells to add, remove, or alter specific genes, like using precise 'cut-and-paste' tools to edit an instruction manual for a living organism. It matters to investors because successful edits can produce new therapies, improve agricultural products, or create commercial advantages; progress, safety, regulatory approvals, and patent control all affect a company’s value and risk profile.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Technology License Partnership provides Genentech access to MaxCyte’s portfolio of platform technologies across research, development, and manufacturing workflows

ROCKVILLE, Md., July 21, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced that it has entered into a technology license partnership with Genentech, a member of the Roche Group, to support the development of cell therapy programs.

The license provides Genentech with access to MaxCyte’s ExPERT GTx^® platform and additional platform technologies across select research, clinical development, and manufacturing workflows. Structured to support multiple programs, the license enables Genentech to support ex vivo applications for cell engineering.                              

The capabilities across MaxCyte platform technologies are designed to streamline the advancement of cell therapy programs by providing integrated access to support cell engineering from early discovery to cGMP manufacturing. The partnership with Genentech underscores MaxCyte’s expertise in enabling next-generation cell therapies by bringing together complementary technologies that support both cell engineering and analytical workflows across the development lifecycle.

“Cell therapy development increasingly requires technology partners that can support programs as they advance from research through development and manufacturing,” said Maher Masoud, President and CEO of MaxCyte. “This partnership allows MaxCyte to provide broader support to Genentech across the cell therapy lifecycle by bringing together complementary capabilities in cell engineering and gene editing. Through integrated access to these platforms, we are helping partners move forward with greater speed, confidence, and continuity.”

About MaxCyte

At MaxCyte^®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation^® technology and SeQure™ gene editing characterization assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping the future of medicine.

Learn more at maxcyte.com and follow us on LinkedIn and Bluesky.

MaxCyte Contacts:

Investor Relations
Gilmartin Group
Erik Abdow
ir@maxcyte.com  

Media Contact
Oak Street Communications
Kristen White
+1 415-608-6060
kristen@oakstreetcommunications.com

FAQ

What did MaxCyte (Nasdaq: MXCT) announce about its partnership with Genentech on July 21, 2026?

MaxCyte announced a technology license partnership with Genentech to support cell therapy development. According to MaxCyte, the agreement grants Genentech access to ExPERT GTx and other platform technologies across research, clinical development, and manufacturing workflows for next-generation cell-based therapeutics.

What technologies does Genentech gain access to under the MaxCyte (MXCT) license partnership?

Genentech gains access to MaxCyte’s ExPERT GTx platform and additional cell-engineering technologies. According to MaxCyte, these platforms support integrated workflows from early discovery through cGMP manufacturing, covering ex vivo cell engineering and associated analytical processes for cell therapy programs.

How does the MaxCyte-Genentech technology license support cell therapy development?

The license supports multiple cell therapy programs by enabling ex vivo cell engineering applications. According to MaxCyte, its platforms are designed to streamline advancement from research through clinical development and manufacturing, offering integrated capabilities in cell engineering, gene editing characterization, and analytical workflows.

Does the MaxCyte (MXCT) partnership with Genentech cover multiple programs or a single project?

The partnership is structured to support multiple cell therapy programs rather than a single project. According to MaxCyte, the license enables Genentech to apply its platform technologies across various ex vivo cell engineering applications within research, clinical, and manufacturing workflows.

What role does MaxCyte’s ExPERT GTx platform play in the Genentech partnership?

ExPERT GTx is a core technology provided to Genentech under the license. According to MaxCyte, this platform, along with other tools, supports high-performance cell engineering across the cell therapy lifecycle, from early discovery through cGMP manufacturing for ex vivo applications.

How does MaxCyte describe the strategic benefit of its Genentech partnership for cell therapies?

MaxCyte describes the partnership as bringing together complementary capabilities in cell engineering and gene editing. According to MaxCyte, integrated access to its platforms aims to help partners advance cell therapy programs with greater speed, confidence, and continuity across development stages.